Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.

Bone marrow transplantation - 1 Aug 2010

Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski L M, Troncy J, Tavtigian S, Gemignani F

Abstract excerpt

High-dose melphalan (HDM) is an essential component in the treatment of patients with multiple myeloma (MM). Few data are available regarding genetic polymorphisms associated with patient outcome or toxicity in this setting. To identify such polymorphisms, we performed a retrospective analysis, genotyping single nucleotide polymorphisms (SNPs) with the arrayed primer extension (APEX) technology in 169 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to DNA Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melphalan

Share to Multiple Myeloma

Share to Pharmaceutical Preparations

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Treatment Outcome

Source

Identifiers

PMID: 19966851
DOI: 10.1038/bmt.2009.335

Genes

ALDH2
BRCA1
ABCB1
RAD51
XRCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.PMID 19966851Read ↗

Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.Semantic proximity Read ↗

Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant.Semantic proximity Read ↗

Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.Semantic proximity Read ↗

GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.Semantic proximity Read ↗

Genetic variations in multiple myeloma II: association with effect of treatment.Semantic proximity Read ↗

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.Semantic proximity Read ↗

The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.Semantic proximity Read ↗

Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.Semantic proximity Read ↗

DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.Semantic proximity Read ↗

Polymorphisms contribution to the determination of significant risk of specific toxicities in multiple myeloma.Semantic proximity Read ↗

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.